|Bid||106.25 x 800|
|Ask||108.50 x 1000|
|Day's range||106.44 - 109.07|
|52-week range||66.89 - 134.76|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||242.57|
|Earnings date||09 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||129.68|
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities. Among this small group of outperformers are two healthcare leaders: biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) and medical device expert DexCom (NASDAQ: DXCM). Let's consider why Vertex Pharmaceuticals and DexCom are excellent stocks to buy.
DexCom (DXCM) closed the most recent trading day at $108.03, moving +0.3% from the previous trading session.